All district medical insurance bureaus, health committees, medical insurance designated medical institutions, and related drug production and operation enterprises:
The selected drugs in the national centralized drug procurement (GY-YD2018-1) have expired on March 31. According to the city’s contract renewal plan, the renewal of the selected products is divided into the following situations: First, 8 selected drugs such as Irbesartan (see the attachment) were reduced to the lowest selected price during the "4+7" expansion, and the agreement period remained. One year, it can be renewed directly; secondly, the competition among the 8 selected drugs such as Fosinopril in the "4+7" pilot and expansion is insufficient, and the status quo is maintained for the time being.
The Municipal Pharmaceutical Affairs Office will sign a tripartite agreement with relevant selected companies and their designated distribution companies for volume purchases. See the attachment for the specific implementation date and procurement cycle.
If a medical institution finds any problems during the procurement process of bid-winning drugs in mass procurement, please report to the Municipal Pharmaceutical Affairs Office in time.
For other matters not covered in this notice, please follow the relevant provisions of Shanghai drug procurement documents and the text of the volume procurement agreement.
Attachment: National Drug Centralized Procurement (GY-YD2018-1) Information Form for Renewal of Selected Drugs in this City
Shanghai Pharmaceutical Centralized Bidding and Purchasing Affairs Management Office
Comments
Post a Comment